Historical record - last NADAC effective date: 4/19/2023
Product Information
FENOFIBRATE 160 MG TABLET is a generic product labeled by Laurus Labs Limited, priced at $0.1206 per EA under NDC 42385093605. Its NADAC has been published 143 times since Sep 2, 2020.
FDA first approved this application on Aug 17, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
160 mg/1
Manufacturer
Laurus Labs LimitedNDC
42385093605
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
4/19/2023
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA210606FDA Approved
8/17/2018
TE Code
AB
On Market Since
1/13/2020
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 160 MG TABLET has been published 143 times since Sep 2, 2020, and over the history we have for it it has declined 53.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1206 per EA |
|---|---|
| All-time high | $0.2802 (May 12, 2021) |
| All-time low | $0.1206 (Apr 19, 2023) |
| Median price | $0.1919 |
| Average price | $0.1979 |
| Largest weekly change | +29.5% (Feb 22, 2023) |
| Weeks tracked | 143 |
| Tracking since | Sep 2, 2020 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-45.1%
All
-53.0%
Last surveyed May 24, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 14% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Laurus Labs Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FENOFIBRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 160 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 160 MG TABLET, manufactured by Laurus Labs Limited, is $0.1206 per EA (NDC 42385093605), effective May 24, 2023.
How has the price of FENOFIBRATE 160 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 160 MG TABLET has declined 53.0%. It has been tracked across 143 weekly CMS publications since Sep 2, 2020.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 160 MG TABLET?
Since Sep 2, 2020, the NADAC for FENOFIBRATE 160 MG TABLET has ranged from a low of $0.1206 (Apr 19, 2023) to a high of $0.2802 (May 12, 2021), with a median of $0.1919 per EA.
Are there cheaper alternatives to FENOFIBRATE 160 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FENOFIBRATE 160 MG TABLET, is $0.1033 per EA — about 14% below FENOFIBRATE 160 MG TABLET.
Who manufactures FENOFIBRATE 160 MG TABLET?
FENOFIBRATE 160 MG TABLET (NDC 42385093605) is labeled by Laurus Labs Limited, and CMS classifies it as a generic product.